Carlyle, SK receive approvals to complete Bluebird Bio acquisition

Bluebird Bio (BLUE), Carlyle (CG), SK Capital Partners, and Beacon Parent Holdings announced that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No further regulatory approvals are required to complete the transaction. The parties expect to complete the merger promptly following the successful completion of the ongoing tender offer, which is scheduled to expire one minute after 11:59 p.m. New York City time on May 12, 2025, unless the tender offer is further extended or earlier terminated. Under the terms of the merger agreement, stockholders will receive an upfront payment of $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, for a total potential value of $9.84 per share. The bluebird board of directors unanimously recommends that stockholders tender into the offer.